127 related articles for article (PubMed ID: 19675744)
41. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
42. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Hong YS; Song SY; Lee SI; Chung HC; Choi SH; Noh SH; Park JN; Han JY; Kang JH; Lee KS; Cho JY
Ann Oncol; 2004 Sep; 15(9):1344-7. PubMed ID: 15319239
[TBL] [Abstract][Full Text] [Related]
43. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
44. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
45. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
[TBL] [Abstract][Full Text] [Related]
46. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
47. The evolution of fluoropyrimidine therapy: from intravenous to oral.
Hoff PM; Cassidy J; Schmoll HJ
Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Stadler WM
Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
[No Abstract] [Full Text] [Related]
50. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
51. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Srinivas S; Guardino AE
BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906
[TBL] [Abstract][Full Text] [Related]
52. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Hernberg M; Virkkunen P; Bono P; Ahtinen H; Mäenpää H; joensuu H
J Clin Oncol; 2003 Oct; 21(20):3770-6. PubMed ID: 14551295
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
54. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
Haarstad H; Jacobsen AB; Schjølseth SA; Risberg T; Fosså SD
Ann Oncol; 1994 Mar; 5(3):245-8. PubMed ID: 8186172
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Vaishampayan UN; Heilbrun LK; Shields AF; Lawhorn-Crews J; Baranowski K; Smith D; Flaherty LE
Invest New Drugs; 2007 Feb; 25(1):69-75. PubMed ID: 16937078
[TBL] [Abstract][Full Text] [Related]
56. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
57. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
58. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
[TBL] [Abstract][Full Text] [Related]
59. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
[TBL] [Abstract][Full Text] [Related]
60. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]